Gefitinib: Difference between revisions
Jump to navigation
Jump to search
David Canner (talk | contribs) No edit summary |
No edit summary |
||
| (6 intermediate revisions by 3 users not shown) | |||
| Line 1: | Line 1: | ||
< | <StructureSection load='' size='450' side='right' scene='Gefitinib/Gefitinib/1' caption='Gefitinib, also known as Iressa'> | ||
__TOC__ | |||
===Better Known as: Iressa=== | ===Better Known as: Iressa=== | ||
* Marketed By: AstraZeneca & Teva | * Marketed By: AstraZeneca & Teva | ||
* Major Indication: Pancreatic & Small | * Major Indication: Pancreatic & Small Cell Lung [[Cancer]] | ||
* Drug Class: [[EGFR]] Inhibitor | * Drug Class: [[EGFR]] Inhibitor | ||
* Date of FDA Approval (Expiration): 2003 (2013) | * Date of FDA Approval (Expiration): 2003 (2013) | ||
| Line 16: | Line 17: | ||
<tr> | <tr> | ||
<td style="width:auto; vertical-align:top;border-width:0px; border-style:inset"> | <td style="width:auto; vertical-align:top;border-width:0px; border-style:inset"> | ||
<div style=" | <div style="height:100%; width: 100%"> | ||
{{:Tyrosine Kinase Inhibitor Pharmacokinetics}} | {{:Tyrosine Kinase Inhibitor Pharmacokinetics}} | ||
</div> | </div> | ||
| Line 22: | Line 23: | ||
</tr> | </tr> | ||
</table> | </table> | ||
</StructureSection> | |||
===References=== | ===References=== | ||
<references/> | <references/> | ||
__NOEDITSECTION__ | __NOEDITSECTION__ | ||